Summary
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease; and SGX302 that is in Phase I/II clinical trial for the treatment of mild-to-moderate psoriasis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate in pre-clinical development for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.
History
Soligenix was founded in 1995. It has since developed proprietary technologies to support the development of innovative therapies that address unmet medical needs in the areas of rare diseases, regenerative medicine, military biodefense and oral mucositis. Soligenix is committed to advancing its innovative platform technologies to improve products and bring unique solutions to patients and physicians worldwide.
Mission
Soligenix’s mission is to provide innovative products to improve the overall health, safety and well-being of people around the world.
Vision
Soligenix’s vision is to be a leader in the development and commercialization of innovative treatments for rare diseases and other unmet medical needs.
Key Team
Dr. Richard C. Straube M.D., MSc. (Sr. VP & Chief Medical Officer)
Mr. Richard L. Dunning (Exec. Officer)
Recognition and Awards
Soligenix has been recognized for its commitment to innovation and received multiple awards for its research and development, including the 2014 FDA Commissioner’s Special Citation for OrbeShield, the only FDA-approved treatment to reduce the severity of radiation-induced oral mucositis.
References
United States 